DK1572133T3 - Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptor - Google Patents
Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptorInfo
- Publication number
- DK1572133T3 DK1572133T3 DK03796966T DK03796966T DK1572133T3 DK 1572133 T3 DK1572133 T3 DK 1572133T3 DK 03796966 T DK03796966 T DK 03796966T DK 03796966 T DK03796966 T DK 03796966T DK 1572133 T3 DK1572133 T3 DK 1572133T3
- Authority
- DK
- Denmark
- Prior art keywords
- human orexin
- receptor
- present
- orexin
- identifying modulators
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2864—Sleep disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43341102P | 2002-12-13 | 2002-12-13 | |
| PCT/US2003/039491 WO2004054510A2 (en) | 2002-12-13 | 2003-12-11 | Method for identifying modulators of human orexin-2 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1572133T3 true DK1572133T3 (da) | 2008-07-14 |
Family
ID=32595183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03796966T DK1572133T3 (da) | 2002-12-13 | 2003-12-11 | Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptor |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7618786B2 (ja) |
| EP (1) | EP1572133B1 (ja) |
| JP (1) | JP2006518709A (ja) |
| AT (1) | ATE391727T1 (ja) |
| AU (1) | AU2003297896A1 (ja) |
| CA (1) | CA2509215A1 (ja) |
| DE (1) | DE60320302T2 (ja) |
| DK (1) | DK1572133T3 (ja) |
| ES (1) | ES2303912T3 (ja) |
| WO (1) | WO2004054510A2 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2557163C (en) | 2004-03-01 | 2011-08-16 | Actelion Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| US10287305B2 (en) | 2016-02-04 | 2019-05-14 | Takeda Pharmaceutical Company Limited | Substituted piperidine compound and use thereof |
| US11059780B2 (en) | 2017-03-08 | 2021-07-13 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| WO2018164192A1 (ja) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| CA3071972A1 (en) | 2017-08-03 | 2019-02-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| EP3816154A4 (en) | 2018-06-29 | 2022-03-30 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF |
| EP3816153B1 (en) | 2018-06-29 | 2023-10-18 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| EP3896060B1 (en) | 2018-12-12 | 2023-08-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US12071434B2 (en) | 2018-12-12 | 2024-08-27 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP7253640B2 (ja) | 2019-01-31 | 2023-04-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589351A (en) * | 1994-12-06 | 1996-12-31 | Nps Pharmaceuticals, Inc. | Fluorescence detection apparatus |
| AU779266B2 (en) * | 2000-05-11 | 2005-01-13 | Banyu Pharmaceutical Co., Ltd. | N-acyltetrahydroisoquinoline derivatives |
-
2003
- 2003-12-11 US US10/537,732 patent/US7618786B2/en active Active
- 2003-12-11 CA CA002509215A patent/CA2509215A1/en not_active Abandoned
- 2003-12-11 JP JP2004560786A patent/JP2006518709A/ja active Pending
- 2003-12-11 EP EP03796966A patent/EP1572133B1/en not_active Expired - Lifetime
- 2003-12-11 AU AU2003297896A patent/AU2003297896A1/en not_active Abandoned
- 2003-12-11 WO PCT/US2003/039491 patent/WO2004054510A2/en active Search and Examination
- 2003-12-11 DE DE60320302T patent/DE60320302T2/de not_active Expired - Lifetime
- 2003-12-11 ES ES03796966T patent/ES2303912T3/es not_active Expired - Lifetime
- 2003-12-11 DK DK03796966T patent/DK1572133T3/da active
- 2003-12-11 AT AT03796966T patent/ATE391727T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| US20060035285A1 (en) | 2006-02-16 |
| WO2004054510A2 (en) | 2004-07-01 |
| CA2509215A1 (en) | 2004-07-01 |
| DE60320302T2 (de) | 2009-05-20 |
| EP1572133A4 (en) | 2007-05-02 |
| ES2303912T3 (es) | 2008-09-01 |
| ATE391727T1 (de) | 2008-04-15 |
| EP1572133B1 (en) | 2008-04-09 |
| WO2004054510A3 (en) | 2007-01-18 |
| AU2003297896A1 (en) | 2004-07-09 |
| US7618786B2 (en) | 2009-11-17 |
| EP1572133A2 (en) | 2005-09-14 |
| JP2006518709A (ja) | 2006-08-17 |
| DE60320302D1 (de) | 2008-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60324430D1 (de) | Methode um rekombinante proteine in cho zellen zu exprimieren | |
| ATE420970T1 (de) | Auf il-1-rezeptor beruhende antagonisten sowie herstellungs- und verwendungsverfahren | |
| DE69932832D1 (de) | Antagonisten auf rezeptorgrundlage und verfahren zur deren herstellung und verwendung | |
| CR11282A (es) | Proteinas enlazadas al antigeno de celula de cepa mcdonough de felino humanas | |
| DK1572133T3 (da) | Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptor | |
| TW200626173A (en) | IL-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses | |
| CY1116364T1 (el) | Αντισωματα της ip-10 και οι χρησεις αυτων | |
| DE69910362D1 (de) | Anwendung der mesenchymalen stammzellen als immunsuppressiva | |
| DE502006007198D1 (de) | Verfahren zur herstellung von permanenten humanen zelllinien | |
| NO20054792L (no) | Nukleinsyresekvenser som koder proteiner assosiert med abiotisk stressrespons og planteceller og planter med okt toleranse for miljobetinget stress | |
| CY1118782T1 (el) | Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια | |
| TR200001861T2 (tr) | Yeni G protein birleştirilmiş alıcı | |
| DK1553975T3 (da) | Optimerede Fc-varianter og fremgangsmåder til generering heraf. | |
| DE69942459D1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
| ATE437652T1 (de) | Verwendung von hmgb1 zur aktivierung dendritischer zellen | |
| DE602005021379D1 (de) | System und verfahren zur produktion von antikörpern in der pflanzenzellkultur | |
| ATE443296T1 (de) | Methoden und system zur identifikation und charakterisierung von peptiden und ihrer funktionellen beziehung mittels berechnung von korrelation | |
| WO2004039334A3 (en) | CALCIUM-SENSING RECEPTOR 2 (CaR2) AND METHODS FOR USING | |
| WO2003059932A3 (en) | Methods of inducing or enhancing connective tissue repair | |
| ATE358721T1 (de) | Cng3b: neuartiger, zyklischer nukleotid- abhängiger kationenkanal | |
| DK1606622T3 (da) | Testfremgangsmåde til bestemmelse af den intracellulære koncentration af cykliske nukleotider | |
| ATE360646T1 (de) | Cng2b: ein putativer humaner zyklische-nukleotid abhängiger ionenkanal | |
| DE60325737D1 (de) | Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen | |
| DE60011785D1 (de) | Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen | |
| WO2005017112A3 (en) | Methods of inhibiting cancer growth by binding to nuclear receptors |